Aspen Neuroscience announced positive 12-month data from its ASPIRO Phase 1/2a clinical trial showing continued safety, tolerability, and sustained clinical benefit in Parkinson's disease patients12
Sasineprocel (ANPD001) is an autologous induced pluripotent stem cell (iPSC)-derived dopaminergic neuron precursor cell therapy that converts patients' own skin cells into neurons for brain implantation25
All eight treated patients in the trial showed marked improvements in symptom control, motor function, and quality-of-life measures at one year5
The therapy does not require immunosuppressive drugs or permanent implantable hardware, eliminating associated adverse events and drug-monitoring requirements23
The company completed Cohort Three dosing in January 2026 and expanded its GMP manufacturing facility in San Diego3
Aspen plans to advance sasineprocel to a Phase 3 pivotal trial later in 20262
In November 2025, Aspen raised $115 million in Series C financing to accelerate clinical development of ANPD0011
Sources:
1. https://aspenneuroscience.com/news-media/press-releases/
2. https://www.morningstar.com/news/pr-newswire/20260318la11383/aspen-neuroscience-announces-positive-12month-data-from-its-aspiro-clinical-trial-in-a-latebreaking-oral-presentation-at-the-adpd-2026-international-conference-on-alzheimers-and-parkinsons-diseases
3. https://www.prnewswire.com/news-releases/aspen-neuroscience-completes-phase-12a-aspiro-trial-cohort-three-dosing-and-state-of-the-art-manufacturing-expansion-paving-the-way-for-developing-transformative-therapies-for-patients-302655800.html
5. https://www.fiercebiotech.com/biotech/aspens-one-year-data-parkinsons-cell-therapy-plants-seeds-ph-3-trial